Sculpture in San Diego

The numbers out of AACR in San Diego this week were, by any honest measure, remarkable. A confirmed response rate of 58% upfront, a hazard ratio of 0.40 in previously treated pancreatic cancer coming up at ASCO.

These are figures which would have seemed highly implausible five years ago.

So this piece isn’t here to pour cold water, rather we exploring what those numbers actually mean for patients who need this drug to work in a community oncology clinic in Ohio, not just a few carefully selected people at academic centres…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers